DE69625516T2 - Verwendung von il-10 zur wundheilung mit verminderter narbenbildung - Google Patents

Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Info

Publication number
DE69625516T2
DE69625516T2 DE69625516T DE69625516T DE69625516T2 DE 69625516 T2 DE69625516 T2 DE 69625516T2 DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T2 DE69625516 T2 DE 69625516T2
Authority
DE
Germany
Prior art keywords
wounds
modified form
partially modified
healing
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625516T
Other languages
German (de)
English (en)
Other versions
DE69625516D1 (de
Inventor
William Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DE69625516D1 publication Critical patent/DE69625516D1/de
Publication of DE69625516T2 publication Critical patent/DE69625516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2066IL-10
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69625516T 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung Expired - Lifetime DE69625516T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Publications (2)

Publication Number Publication Date
DE69625516D1 DE69625516D1 (de) 2003-01-30
DE69625516T2 true DE69625516T2 (de) 2003-09-25

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625516T Expired - Lifetime DE69625516T2 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Country Status (13)

Country Link
US (2) US6387364B1 (enExample)
EP (1) EP0871473B1 (enExample)
JP (1) JP4050317B2 (enExample)
AT (1) ATE229814T1 (enExample)
AU (1) AU719089B2 (enExample)
CA (1) CA2229078C (enExample)
DE (1) DE69625516T2 (enExample)
DK (1) DK0871473T3 (enExample)
ES (1) ES2187665T3 (enExample)
GB (1) GB2304047A (enExample)
PT (1) PT871473E (enExample)
WO (1) WO1997005894A1 (enExample)
ZA (1) ZA966744B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941108B1 (en) * 1996-12-04 2002-10-16 Renovo Limited Wound healing and treatment of fibrosis
WO1998033516A1 (en) * 1997-02-05 1998-08-06 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
CA2384076A1 (en) * 1999-09-08 2001-03-15 Schering Corporation Novel uses of mammalian ccr6 receptors and related reagents
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
US20030148952A1 (en) * 2001-10-18 2003-08-07 Crombleholme Timothy M. Methods and materials for the recruitment of endothelial cells
NZ573737A (en) * 2003-07-15 2011-06-30 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds comprising a PKC modulator
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス, インコーポレイテッド 創傷治癒のための改善された方法および組成物
CN101835486B (zh) * 2007-07-30 2012-12-12 希尔洛有限公司 用于治疗创伤的药物组合物以及相关方法
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
JP2011507862A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス, インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシン43ポリヌクレオチドの使用
JP2011507856A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス, インコーポレイテッド 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用
WO2009120799A2 (en) * 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
EP3348281B1 (en) 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
CN102325789A (zh) * 2009-02-24 2012-01-18 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
EP2691515A2 (en) * 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
AU2013263502B2 (en) * 2012-05-18 2018-02-08 Otago Innovation Limited Combination treatments and compositions for wound healing
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
KR20170068553A (ko) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−10を使用する方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン10の使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
DE3889479T2 (de) 1987-02-27 1994-12-22 Eastman Kodak Co Mit Nieder-pI-Protein beschichtete Membranstruktur und Verfahren zu ihrer Herstellung und Verwendung.
JPH0611706B2 (ja) * 1989-01-20 1994-02-16 ザ ユニバーシティ オブ メルボルン フィブリン溶解
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
EP0502080A4 (en) * 1989-11-21 1993-02-10 The University Of Melbourne Anti-inflammatory compositions and methods
DK0526544T3 (da) 1990-04-11 1999-06-21 Brigham & Womens Hospital Terapeutiske anvendelser af actinbindende forbindelser
JPH0747545B2 (ja) * 1991-01-10 1995-05-24 シェリング・コーポレーション 創傷治癒及び修復の修復段階を促進し、かつ感染した創傷及び糖尿病哺乳類の創傷の治癒を促進するためのil−4の用途
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU8647991A (en) 1991-08-26 1993-03-16 State of Oregon Acting by and Through The State of Board of Higher Education on Behalf of The Oregon Health Sciences University, The Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury
IL110413A0 (en) 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
JP4083794B2 (ja) * 1994-03-29 2008-04-30 レノボ・リミテッド 創傷の治癒
EP1621206A1 (en) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Also Published As

Publication number Publication date
JP4050317B2 (ja) 2008-02-20
GB9516287D0 (en) 1995-10-11
CA2229078C (en) 2010-04-20
CA2229078A1 (en) 1997-02-20
ZA966744B (en) 1998-02-09
EP0871473B1 (en) 2002-12-18
DK0871473T3 (da) 2003-04-14
JPH11510505A (ja) 1999-09-14
PT871473E (pt) 2003-03-31
ATE229814T1 (de) 2003-01-15
WO1997005894A1 (en) 1997-02-20
AU6666096A (en) 1997-03-05
AU719089B2 (en) 2000-05-04
EP0871473A1 (en) 1998-10-21
GB2304047A (en) 1997-03-12
US6387364B1 (en) 2002-05-14
US20020128447A1 (en) 2002-09-12
ES2187665T3 (es) 2003-06-16
US7052684B2 (en) 2006-05-30
DE69625516D1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
US7052684B2 (en) Methods of healing wounds and fibrotic disorders using IL-10
DE3782358T2 (de) Wundheilende zusammensetzung.
DE68924069T2 (de) Kollagen-wundheilmatrizen und verfahren zur herstellung.
DE69002795T2 (de) Stabilisierte, den epidermalen Wachstumsfaktor enthaltende Mittel.
EP1526867B1 (de) Erythropoietin in subpolycythämischen dosen
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE69231486T2 (de) Zusammensetzung enthaltend pdgf und dexamethason zur förderung von gewebsreparatur und -regenerierung
DE69228949T2 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE60130008T2 (de) Proteinkombinationen zur heilung von wunden
DE69119879T2 (de) Epitheliocytenwachstumsbeschleuniger
EP0203580B1 (de) Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen
DE69033703T2 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
DE69031218T2 (de) Wundheilung
DE3781250T2 (de) Verwendung vom "cartilage-inducing faktor b(cif-b)" zur herstellung eines arzneimittels gegen das wachstum von tumoren.
DE69633396T2 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
DE69009748T2 (de) Fgf enthaltende stabilisierte zubereitungen.
DE3853721T2 (de) Verwendungen von rekombinantem koloniestimulierendem faktor-1.
DE69716460T2 (de) Wundheilung und behandlung von fibrose
DE69626987T2 (de) Pharmaceutische komposition
DE69211723T2 (de) Mit einem Zellwachstumsfaktor bewirkte Anregung von Wachstum im Knocheninneren
DE69819563T2 (de) Topische zusammensetzung enthaltend menschlichen epidermalen wachstumsfaktor
EP0493662B1 (de) Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge
DE69626050T2 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
DE60116982T2 (de) Verwendung einer Stutenmilchfraktion ausgewählt aus Magermilch, Molke und Natriumcaseinat mit entzündungshemmender Wirkung
AT403434B (de) Topische zusammensetzung zur beschleunigung der wundheilung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition